Digest Network Come funziona
Network
/
Società
Af
Non verificato

Affinia Therapeutics

Di cosa scriviamo

BiotecnologiaCardiologiaFarmaceuticaMedicina - VarieSalute

14 comunicati stampa

Guarda tutti i comunicati
09/10/2026
Eventi
Industria
Salute
Igiene alimentare
Biotecnologia
Medicina - Varie
Farmaceutica
Cardiologia
Affinia Therapeutics’ AFTX-201 and UPBEAT™ Clinical Trial in BAG3 DCM Featured at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026
Fonte
Affinia Therapeutics
Emittente
Business Wire
1.00
0
22/07/2026
Industria
Cardiologia
Biotecnologia
Farmaceutica
Sanità
Salute
Igiene alimentare
Medicina - Varie
FDA Grants Orphan Drug Designation to Affinia Therapeutics’ AFTX-201 for the Treatment of BAG3-Associated Dilated Cardiomyopathy (DCM)
Fonte
Affinia Therapeutics
Emittente
Business Wire
1.00
0
14/05/2026
Eventi
Igiene alimentare
Salute
Biotecnologia
Medicina - Varie
Cardiologia
Affinia Therapeutics Presents AFTX-201 Data and UPBEAT© Clinical Trial Design for BAG3-Associated Dilated Cardiomyopathy, Alongside Advances in BBB-Penetrant AAV Capsids and Proprietary Manufacturing, at the 29th ASGCT  2026 Annual Meeting
Fonte
Affinia Therapeutics
Emittente
Business Wire
1.00
0
28/04/2026
Eventi
Salute
Biotecnologia
Scienza
Farmaceutica
Cardiologia
Affinia Therapeutics to Present AFTX-201 for BAG3-Associated Dilated Cardiomyopathy (DCM) and Highlight Proprietary Capsid Engineering and Manufacturing Data at the American Society of Gene & Cell Therapy 2026 Annual Meeting
Fonte
Affinia Therapeutics
Emittente
Business Wire
1.00
0
06/04/2026
Industria
Scienza
Sanità
Farmaceutica
HIV, AIDS e malattie autoimmuni
Biotecnologia
Medicina - Varie
Cardiologia
Igiene alimentare
Salute
Affinia Therapeutics Receives Approval from Health Canada to Initiate the UPBEAT© Trial, a Phase 1/2 Clinical Trial to Investigate AFTX-201 as a Treatment for BAG3-Associated Dilated Cardiomyopathy (DCM)
Fonte
Affinia Therapeutics
Emittente
Business Wire
1.00
0
04/03/2026
Industria
Scienza
Igiene alimentare
Biotecnologia
Medicina - Varie
Cardiologia
Salute
Farmaceutica
Affinia Therapeutics Granted FDA Fast Track Designation for AFTX-201 as a Treatment for People Living with BAG3-Associated Dilated Cardiomyopathy (DCM)
Fonte
Affinia Therapeutics
Emittente
Business Wire
1.00
0
18/02/2026
Scienza
Igiene alimentare
Biotecnologia
Medicina - Varie
Cardiologia
Salute
Farmaceutica
Industria
Affinia Therapeutics Receives European Medicines Agency Orphan Drug Designation for AFTX-201 in BAG3-Associated Dilated Cardiomyopathy (DCM)
Fonte
Affinia Therapeutics
Emittente
Business Wire
1.00
0
04/02/2026
Industria
Scienza
Igiene alimentare
Biotecnologia
Medicina - Varie
Cardiologia
Salute
Farmaceutica
Affinia Therapeutics Announces FDA Acceptance of IND Application to Advance AFTX-201 to a Phase 1/2 Trial for the Treatment of BAG3-Associated Dilated Cardiomyopathy (DCM)
Fonte
Affinia Therapeutics
Emittente
Business Wire
1.00
0
14/10/2025
Associazioni/Professionisti
Salute
Biotecnologia
Sanità
Finanza
Farmaceutica
Cardiologia
Eventi
Affinia Therapeutics to Participate in Upcoming Investor Conferences
Fonte
Affinia Therapeutics
Emittente
Business Wire
1.00
0
07/10/2025
Salute
Tecnica
Biotecnologia
Medicina - Varie
Cardiologia
Affinia Therapeutics Announces Series C Financing to Advance New Class of Gene Therapies Intended to Provide Improved Safety and Efficacy
Fonte
Affinia Therapeutics
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0